Navigation Links
Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
Date:6/20/2013

PISCATAWAY, N.J., June 20, 2013 /PRNewswire/ -- On June 13, 2013, the United States Supreme Court unanimously ruled that although isolated, natural gene sequences are unpatentable, cDNA (referred to as synthetic DNA) is officially considered patentable subject material. The ruling was issued after the court reviewed patents owned by Myriad Genetics Inc. in the high-profile case Association for Molecular Pathology v. Myriad Genetics. The patents claimed the genes BRCA1 and BRCA2, as well as methods for detecting mutations in the genes that have been linked to breast and ovarian cancer. The court supported this legal claim, stating that "cDNA is not a 'product of nature,' so it is patent eligible …".

GenScript's gene synthesis service is a valuable method for circumventing the isolation of natural DNA sequences for use in biological research studies. The service provides non-natural, de novo DNA sequences synthesized according to specified client design, allowing natural gene sequences or cassettes to be engineered for in vivo, or in vitro use, including diagnostic tests. Additionally, GenScript's OptimumGene(TM) codon optimization technology can alter the sequence of natural genes, to increase the expression of the subsequent protein in a number of systems. The OptimumGeneTM algorithm considers nearly every parameter affecting the central dogma process, from transcription to protein folding, and has been proven to optimize protein production in bacterial, mammalian, yeast and insect expression systems. OptimumGeneTM codon optimization in combination of gene synthesis can generate novel, non-naturally occurring sequences, with high-utility and attractive patentable features. To preserve clients' intellectual property rights, GenScript does not claim any rights to specialized synthetic or OptimumGeneTM codon optimized genes. Custom project details are kept strictly confidential; all intellectual property rights belong to the client.

It may be too soon to speculate on the court ruling's effect on DNA sequences' future patentability. However, as the pace of molecular biology research quickens, the use of synthetic DNA will inevitably become a mainstay in every lab. GenScript offers gene synthesis and codon optimization solutions for the present and future of gene patent law and remains committed to supporting innovation.

*GenScript is not a legal practitioner and the content above is in no way intended to provide legal advice for patent prosecution, litigation or any associated legal matters thereof.


'/>"/>
SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... A ... mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying ... on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
(Date:5/15/2019)... FALLS, Wis. (PRWEB) , ... May 16, 2019 ... ... oil and water mixtures. As a result, food and beverage products rely on ... today, consumers demand more natural sounding label declarations. This paradigm shift triggers food ...
(Date:5/4/2019)... PAULO, Brazil (PRWEB) , ... May 03, 2019 ... ... lecture given by the President of the Dakila Pesquisas Association, the scientist and ... the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research ...
Breaking Biology Technology:
(Date:6/11/2019)... ... , ... Improved Pharma LLC announces the publication of “Predictive and Accelerated Formulation ... was published online on April 29th, 2019. The authors are Stephen R. Byrn ... Purdue University. , The article is the most recent addition to a theme dedicated ...
(Date:6/4/2019)... ... June 04, 2019 , ... ... appointment of Susan Murphy as the new President of Molecular Devices, replacing Greg ... Devices’ parent company, Danaher Corporation. , Since joining Molecular Devices in a scientific ...
(Date:6/1/2019)... ... May 31, 2019 , ... ... Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. ... securing value-added institutional investors who bring significant financial and business resources to bear ...
Breaking Biology News(10 mins):